German ban of glyphosate from 2023 is bitter failure for BayerThe German government has decided to ban glyphosate-based weedkillers, such as Bayer's Roundup, from 2023 to foster insect variety, Handelsblatt (p19&34), Süddeutsche Zeitung (SZ) (p1) and Frankfurter Allgemeine Zeitung (FAZ) (p1&17&19) reported on Thursday.
Bayer poaches J&J managerBayer has attracted Marianne De Backer, a specialist for acquisitions and cooperations from its competitor Johnson & Johnson, FAZ (p18) and SZ (p18) reported on Wednesday (APMHE 64230).
'No illegal behaviour' in Monsanto's file, says external auditMonsanto did not behave illegally in compiling lists of supportive and critical stakeholders according to an external audit commissioned by the company's new owner, Bayer, Handelsblatt (p26) and FAZ (p26) report on Friday.
Frankfurt staff hope for positive news from Sanofi's new CEOStaff at Sanofi's Frankfurt site are hoping that the French group's new chief executive Paul Hudson will step back from job cuts announced for Germany, FAZ reported on Tuesday (p24).
Paradigm shift for MorphoSysJean-Paul Kress taking over as CEO of German biotech MorphoSys from founder Simon Moroney is a "paradigm shift", Handelsblatt said on Tuesday (p26-27).
Merz criticises 'wealth tax' plansGerman pharma aesthetic company Merz warned about social democrat party SPD's plans to establish a "wealth tax" and its the potential negative impact on investments, FAZ reported on Wednesday (p22) (APMHE 64242).
Chemical industry lowers prognosis for the third time this yearThe association of the German chemical industry VCI has lowered its forecast for the pharmaceutical and chemical sector for the third time this year, expecting a sales fall of 5% to €193 billion, FAZ reported on Thursday (p17&18).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.